Litigation Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2019)

CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2019)

Docket		Date Filed	2019-06-19
Court	District Court, D. New Jersey	Date Terminated	2021-03-10
Cause	15:1126 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	APOTEX INC.; CELGENE CORPORATION
Patents	6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,468,363; 7,855,217; 8,315,886; 8,404,717; 8,626,531; 8,741,929; 9,056,120
Attorneys	CHARLES MICHAEL LIZZA; ROBERT J. SCHOENBERG
Firms	Quinn Emanuel Uquhart & Sullival LLP; Saul Ewing Arnstein & Lehr LLP
Link to Docket	External link to docket

Biologic Drugs cited in CELGENE CORPORATION v. APOTEX INC.

Details for CELGENE CORPORATION v. APOTEX INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-06-19				External link to document
2019-06-19	1	Complaint	alleging that the claims of U.S. Patents No. 6,315,720 (“the ’720 patent”), 6,561,977 (“the …219 patent”), and 8,431,598 (the “’598 patent”), all owned by Celgene (collectively, “the patents-in-…PageID: 7 ’977 patent”), 6,755,784 (“the ’784 patent”), 8,315,886 (“the ’886 patent”), 8,626,531 (“the…“the ’531 patent”), 7,465,800 (“the ’800 patent”), 7,855,217 (“the ’217 patent”), 7,468,363 (“the ’363…claims of U.S. Patents No. 7,189,740 (“the ’740 patent”), 8,404,717 (“the ’717 patent”), and 9,056,120	External link to document